---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-045000"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T06:15:42.473650+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Foghorn posts Q3 net loss of $19.1M; first patient dosed in Phase 1 for FHD-909

## Summary
- Revenue $7.8M vs $17.5M year ago; net loss $19.1M vs $14.3M year ago.
- Cash $267.4M as of Sept 30, 2024; expects cash runway into 2027.
- First patient dosed with FHD-909 (SMARCA2 inhibitor) in Phase 1 for SMARCA4 mutant NSCLC.
- Topline Phase 1 data for FHD-286 + decitabine in AML expected by year-end 2024.
- Appointed Anna Rivkin as Chief Business Officer in September 2024.

## SEC filing metadata
- accession: 0001628280-24-045000
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828024045000/0001628280-24-045000-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828024045000/fhtx-20241104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-045000
- JSON: https://secwatch.observer/filing/0001628280-24-045000.json
- Plain text: https://secwatch.observer/filing/0001628280-24-045000.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.